TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Histone Deacetylase Inhibitors (HDAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* age: 20 and older~* body mass index 19-30 kg/sq m~* willingness to maintain normal exercise and activity patterns~* willingness to avoid cruciferous vegetables and garlic and related foods (onion etc.) 1 week before and 2 weeks during the trial for a total of 3 weeks~Exclusion criteria:~* tobacco use within the past three months~* engaging in aerobic activity more than 6 hours per week~* being vegetarian or having other restrictive dietary requirements~* consuming \>3 alcoholic beverages/day or \>10 per week~* having history of diabetes or uremia or other known metabolic disease~* participating in another dietary study within the past three months~* for women, being pregnant or breastfeeding~* gastrointestinal diseases that could increase gut permeability, including Crohn's disease, ulcerative colitis, gastritis~* taking dietary supplements other than those given in the study~* abnormal liver function, CBC, or thyroid values~* individuals taking any drug or medication, prescription or over the counter, including Isoniazid, Saquinavir, Warfarin, Cyclosporine, Acetaminophen, Oxazepam, medications used for HIV/ AIDS, blood clotting, birth control pills, fish oil and medications metabolized by CYPs (CYP1A2, CYP2E1 and CYP3A4) during the dosing period of 1 week and 48 h prior to and after dosing. Exceptions may be made by the study MD and the PI if in their opinion a medication will not interfere with the scientific validity of the study. The study MD will evaluate a medication on a case-by-case basis to determine that efficacy and safety are not adversely affected.~* Individuals who are known to have problems with blood clotting or increased bleeding, including hemophiliacs or anyone recently undergoing or recovering from a surgical procedure.~* soy or garlic allergy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BSE placebo & garlic oil placebo (Type: PLACEBO_COMPARATOR): Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
- garlic oil plus BSE placebo (Type: ACTIVE_COMPARATOR): one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
- BSE plus garlic oil placebo (Type: ACTIVE_COMPARATOR): two BSE capsules plus one garlic oil placebo capsule per day for seven days
- BSE & Garlic Oil (Type: ACTIVE_COMPARATOR): two BSE and one garlic oil capsule per day for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Round Window Versus Cochleostomy Approach to CI Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria are:~* 18 years of age or older,~* less than a 10-year duration of deafness in the ear to be implanted,~* primary surgery,~* normal shaped cochleae,~* no retrocochlear pathology, and~* grossly normal cognitive function.~Exclusion criteria are:~* less than 18 years of age,~* prelingual deafness, or~* greater than 10-years duration of deafness in the ear to be implanted;~* prior otologic surgery in the implanted ear (excluding tympanostomy tube placement),~* inner ear malformation present in the ear to be implanted,~* retrocochlear pathology present in the auditory system to be implanted,~* developmental delay or known cognitive impairment, or~* pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- round window (Type: ACTIVE_COMPARATOR): Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
- cochleostomy (Type: ACTIVE_COMPARATOR): Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Argatroban Versus Lepirudin in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thrombocytopenia suspicious for HIT with decrease in platelet count \>50% from baseline obtained at hospital admission~* 4 T´s score for HIT probability \>3 AND/OR positive ELISA for HIT~* Age ≥18 years~* Informed consent (if applicable)~Exclusion Criteria:~* Transient thrombocytopenia due to intraoperative bleeding~* Active bleeding~* Intracranial operations~* Liver dysfunction with spontaneous aPTT\> 60 sec.~* History of adverse events or sensitivity against study drugs~* Pregnancy~* Age\<18 years~* Preexisting psychiatric/neurologic disorders with long-term inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PR1 (Type: ACTIVE_COMPARATOR): Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
- PR2 (Type: ACTIVE_COMPARATOR): Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Oral Contrast in the Large Intestine on the Recognition of Appendix

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 14 years to 120 years~* patients that underwent an ultrasound exam that proved to be equivocal or not diagnostic~* patients who were sent to perform a CT scan that includes drinking oral contrast material.~Exclusion Criteria:~* pregnant patients~* patients with known allergy to oral contrast material (TELEBRIX gastro)

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- first (Type: EXPERIMENTAL): a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Supportive Treatment of Severe Heart Failure by Renal Denervation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA III-IV~* ejection fraction \<45 %~* 6-minute walking test under 440m~Exclusion Criteria:~* Unstable hemodynamic state~* uncooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal nervous denervation. (Type: ACTIVE_COMPARATOR): Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
- Renal nervous denervation (delayed) (Type: ACTIVE_COMPARATOR): Renal nervous denervation is performed after six months on the waiting list

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed locally advanced breast cancer~  * T3 inoperable, N0-N2~ * Any T, N2~ * T4, N0-N2~ * Inflammatory breast carcinoma~* Prior treatment with 4-6 courses of standard induction chemotherapy or active investigational regimens completed within the past 4 weeks~* Residual tumor size less than 5 cm~* No fixed axillary lymph nodes~* No multifocal or bilateral breast cancer~* No clinical suspicion of extensive ductal carcinoma in situ~* No unresolved skin edema~* No distant metastases (including ipsilateral supraclavicular node)~  * Positive bone scan allowed provided there are no bone metastases on x-ray~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* Any age~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Neutrophil count at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 times normal~* SGOT and SGPT no greater than 2 times normal~* Alkaline phosphatase no greater than 2 times normal~Renal:~* Creatinine less than 1.5 times normal~Other:~* No other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or adequately treated cone-biopsied carcinoma in situ of the cervix~* No serious underlying medical illness that would preclude study~* No psychiatric or addictive disorder that would preclude study~* No contraindication to study treatment~* Not pregnant~* Fertile patients must use effective barrier contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* No concurrent hormonal replacement therapy~* No concurrent oral contraceptives~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy for breast cancer~Surgery:~* No prior surgery for breast cancer other than biopsy for diagnosis confirmation~Other:~* No other prior systemic therapy for breast cancer

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have a documented diagnosis of Duchenne Muscular Dystrophy (DMD) confirmed by complete dystrophin deficiency (by immunofluorescence and/or immunoblot), or identifiable mutation in the DMD gene where reading frame can be predicated as out of frame, or complete dystrophin gene sequencing consistent with DMD; AND in the opinion of the Investigator, a typical clinical profile consistent with DMD.~2. Participants taking approved treatments for DMD (by a Health Authority) that target dystrophin gene mutations (e.g., eteplirsen or ataluren) may be enrolled in the study if they have been on a stable dose for 30 days prior to the first dose of study drug, and plan to remain on that dose throughout the study.~Exclusion Criteria:~1. Participant has had previous systemic treatment with corticosteroids within 2 months prior to the Screening Visit. Exception: In subjects who were down-titrated to a physiological dose of corticosteroids (ie, 3mg/m2 of prednisone or deflazacort) a maximum of 1 month of no greater than a physiological dose followed by 1 month completely off corticosteroids prior to the Screening Visit will be acceptable for study entry. Transient previous use of corticosteroids will be evaluated on a case-by-case basis by the sponsor or designee. The use of topical or intra-articular corticosteroids is permitted during the study~2. Participant is unable to complete the 10 meter Walk/Run test at the Screening and/or Baseline Visit.~3. Participant has Type 1 or Type 2 diabetes mellitus.~4. Participant has a history of chronic active hepatitis including acute or chronic hepatitis B, or acute or chronic hepatitis C.~5. Participant has a history of tuberculosis (TB) infection, any signs/symptoms of TB, or any close contact with an individual with an active TB infection.~6. Participant has known immune compromised status (not related to disease/condition under study), including but not limited to, individuals who have undergone organ transplantation or who are known to be positive for the human immunodeficiency virus.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Period 1: MNK-1411 (Type: EXPERIMENTAL): Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
- Period 1: Placebo (Type: EXPERIMENTAL): Participants receive placebo at a volume appropriate to body weight during Period 1
- Period 2: MNK-1411 (Type: EXPERIMENTAL): All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Single/Double lung transplantation~* at least 6 months after lung transplantation~* bronchiolitis obliterans syndrome, Stadium \> 1 (nach ISHLT 2001, FEV1 \<80% Best), none other reason for worsening lung function (eg acute rejection, infection, extrapulmonary reasons, airway obstruction)~* none gastroesophageal reflux~* medication for \> 3 months with Azithromycin with further decrease of FEV1, MEF 25-75~* bioptic prove that there is no acute rejection~* no improvement under steroid pulse therapy~Exclusion Criteria:~* tumor or hematologic disease~* acute rejection~* respiratory insufficiency (O2\>2l/min, pCO2 \>50 mm Hg)~* weight \< 40 kg~* acute infection~* colonization with multiresistant pathogens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
- 2 (Type: ACTIVE_COMPARATOR): 2-day cycles of photopheresis every 3 weeks for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Tissue Oxygen Monitoring in Critically Injured Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Intubated and assisted mechanical ventilation~* Traumatic brain injury requiring advanced neuromonitoring~* Abbreviated injury scale 3 or more in torso. abdomen, or extremities~Exclusion Criteria:~* Age less than 18 years~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Implement and Evaluate REFLECT Communication Curriculum for Oncology Based Medical Graduate Students

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects: Resident or Fellow enrolled in an oncology related training program (Radiation Oncology, Medical Oncology, Palliative Medicine and Hospice Care, Neurooncology).~* Location: Mayo Clinic Arizona.~* Interest: Willingness to participate.~Exclusion Criteria:~* Schedule does not permit to participation.~* Not enrolled in an oncology-based residency or fellowship at Mayo Clinic Arizona.~* Interest: Not willing to participate.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Standard oncology curriculum for medical trainees in oncology programs.
- Reflective Group (Type: EXPERIMENTAL): Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 45-69~* body mass index 20-30 kg/m2~* willingness to hold physical activity constant over study duration~* written informed consent~Exclusion Criteria~* smoking~* hypertension (\> 140/90 mm Hg)~* hypotension (men \< 115 mm Hg; women \< 105 mm Hg)~* obesity (BMI =/\> 30 kg/m2)~* vegan~* infections in the last 6 weeks~* allergy for food (e.g., milk)~* pregnancy~* diabetes (elevated fasting blood glucose level)~* clinical known coronary diseases~* acute and/or chronical medication (incl. contraceptive)~* abnormal kidney function~* abnormal liver function~* known cardiac arrhythmia (e.g., atrial fibrillation)~* blood parameters (ALAT, Creatinin, Hb, potassium, CRP) in range

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- ruminant TFA (Type: ACTIVE_COMPARATOR): In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
- industrial TFA (Type: ACTIVE_COMPARATOR): In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
- without TFA (Type: PLACEBO_COMPARATOR): In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients recommended for coronary bypass surgery (preferably with cardiopulmonary support)~* Ejection fraction ≥15% and ≤35%~* Left ventricular myocardial infarction (MI - heart attack) ≥4 weeks prior to screening~Exclusion Criteria:~* Need for a rapid surgical coronary revascularization~* Need for any other related cardiosurgical measure during coronary surgery (e.g. mitral valve repair or valve replacement)~* Patients with a left ventricular aneurysm who is a candidate for left ventricular aneurysmectomy or left ventricular reduction surgery; patient receiving left or biventricular (BiV) pacing therapy for heart failure (unless the patient has stabilized after 6 or more months of this therapy)~* Cardiomyopathy presumed to be of non-ischemic origin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study- Contribution of Tomosynthesis In Locoregional Pretherapeutic Staging of a Breast Tumor: Multicentricity Search

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years.~* Patients with a breast tumor, regardless of the stage and size~* Compulsory affiliation to a social security system.~* Obtaining informed consent in writing, signed and dated.~Exclusion Criteria:~* Patients with cognitive or psychiatric disorders.~* Patient deprived of liberty by a court or administrative.~* Patients with indications against the achievement of MRI, mammography and tomosynthesis~* Pregnant Women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues